10.0. Conclusion
Cost effectiveness analysis is the principal method for examining the efficiency of health interventions, with both widespread acceptance and official sanction from a number of governmental agencies. Although some have criticized such analyses as a means on which to base decisions, three important caveats to the use of CEA are necessary. First, such analyses are models that attempt to estimate efficiency, but the application of such analyses should always question the models assumptions to ascertain if they are applicable in a particular urban setting. Second, users and analysts of CEA should carefully assess the uncertainty in the analysis. Too often, the base case analysis receives the bulk of attention in an attempt to classify an intervention as “cost effective” or not. Appropriate attention to the assessment of uncertainty is important for identifying questions that are important for making better decisions. Finally, CEA — even if accepted as a good measure of efficiency — is only one attribute that decision makers should consider when making resource allocation decisions. CEA can be an important input to such decisions, but so are considerations of politics, law, ethics and justice. Resource allocation decisions will remain complicated without simple technical solutions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnesen, T., and Nord, E. (1999). The value of DALY life: Problems with ethics and validity of disability adjusted life years. BMJ. 319:1423–5.
Aynalem, G., Mendoza, P., Frederick, T., and Mascola, L. (2004). Who and why? HIV-testing refusal during pregnancy: implication for pediatric HIV epidemic disparity. AIDS Behav. 8:25–31.
Bayoumi, A.M., and Redelmeier, D.A. (1999). Economic methods for measuring the quality of life associated with HIV infection. Qual. Life Res. 8:471–80.
Birch, S., and Donaldson, C. (2003). Valuing the benefits and costs of health care programmes: where’s the ‘extra’ in extra-welfarism? Soc. Sci. Med. 56:1121–1133.
Bleichrodt, H. (2002). A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 11:447–56.
Bleichrodt, H., and Johannesson, M. (1997). The validity of QALYs: An experimental test of constant proportional tradeoff and utility independence. Med. Decis. Making 17:21–32.
Bombardier, C., Wolfson, A.D., Sinclair, A.J., and McGeer, A. (1982). Comparison of three preference measurement methodologies in the evaluation of a function status index. In: Deber, R.B. and Thompson, C.G. (eds.), Choices in health care: decision-making and evaluation of effectiveness. Toronto, pp. 145–159.
Briggs, A.H., Goeree, R., Blackhouse, G., and O’Brien, B.J. (2002). Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med. Decis. Making 22:290–308.
Briggs, A.H., O’Brien, B.J., and Blackhouse, G. (2002). Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public Health 23:377–401.
Briggs, A.H., Wonderling, D.E., and Mooney, C.Z. (1997). Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 6:327–340.
Brouwer, W.B., and Koopmanschap, M.A. (2000). On the economic foundations of CEA. Ladies and gentlemen, take your positions! J. Health Econ. 19:439–59.
Bulterys, M., Jamieson, D.J., O’Sullivan, M.J., Cohen, M.H., Maupin, R., Nesheim, S., Webber, M.P., Van Dyke, R., Wiener, J., and Branson, B.M. (Mother-Infant Rapid Intervention At Delivery (MIRIAD) Study Group). (2004). Rapid HIV-1 testing during labor: a multicenter study. JAMA. 292(2):219–23
Canadian Coordinating Office for Health Technology Assessment (1997). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa.
Carr-Hill, R.A. (1989). Assumptions of the QALY procedure. Soc. Sci. Med. 29:469–77.
Cartwright, W.S. (1999). Costs of drug abuse to society. J Ment. Health Policy Econ. 2:133–134.
Clark, P.A. (2003). The ethics of mandatory HIV testing of all pregnant women. Linacre. Q. 70:2–17.
Claxton, K. (1999). The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J. Health Econ. 18:341–364.
Culyer, A.J. (2001). Equity-some theory and its policy implications. J. Med. Ethics 27:275–83.
Culyer, A.J., and Wagstaff, A. (1993). Equity and equality in health and health care. J. Health Econ. 12:431–57.
Davis, M. (2004). Planet of Slums. New Left Review 26:5–34.
Deber, R.B., and Goel, V. (1990). Using explicit decision rules to manage issues of justice, risk, and ethics in decision analysis: when is it not rational to maximize expected utility? Med. Decis. Making 10:181–94.
Detsky, A.S., and Naglie, I.G. (1990). A clinician’s guide to cost-effectiveness analysis. Ann. Intern. Med. 113:147–54.
de Zulueta, P. (2000). The ethics of anonymized HIV testing of pregnant women: a reappraisal. J. Med. Ethics 26:16–21.
Diehr, P., Yanez, D., Ash, A., Hornbrook, M., and Lin, D.Y. (1999). Methods for analyzing health care utilization and costs. Annu. Rev. Public Health 20:125–44.
Diener, A., O’Brien, B., and Gafni, A. (1998). Health care contingent valuation studies: a review and classification of the literature. Health Econ. 7:313–26.
Dolan, P., Gudex, C., Kind, P., and Williams, A. (1996). Valuing health states: A comparison of methods. J. Health Econ. 15:209–31.
Drummond, M.F., Stoddart, G.L., and Torrance, G.W. (1987). Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford.
Fleming, P.L., Byers, R.H., Sweeney, P.A., Daniels, D., Karon, J.M., and Janssen, R.S., 2000, HIV Prevalence in the United States, 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA (September 16, 2004); http://www.retroconference.org/2002/Abstract/13996.htm.
Freemantle, N. (2000). Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. BMJ. 320:1156–1157.
Fenwick, E., Claxton, K., and Sculpher, M. (2001). Representing uncertainty: the role of cost-effectiveness acceptable curves. Health Econ.
Froberg, D.G., and Kane, R.L. (1989a). Methodology for measuring health-state preferences-I: Measurement strategies. J. Clin. Epidemiol. 42:345–54.
Froberg, D.G., and Kane, R.L. (1989b). Methodology for measuring health-state preferences-III: Population and context effects. J. Clin. Epidemiol. 42:585–92.
Fryback, D.G. (1993). QALYs, HYEs, and the loss of innocence. Med. Decis. Making 13:271–2.
Gafni, A., and Birch, S. (1993). Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. CMA. 148:913–7.
Garber, A.M., and Phelps, C.E. (1997). Economic foundations of cost-effectiveness analysis. J. Health Econ. 16:1–31.
Garber, A.M., Weinstein, M.C., Torrance, G.W., and Kamlet, M.S. (1996). Theoretical foundations of cost-effectiveness analysis. In: Gold, M.R., Seigel, J.E., Russell, L.B., and Weinstein, M.C. (eds.) (1996). Cost-effectiveness in health and medicine. Oxford University Press, New York, NY.
Gold, M.R., Seigel, J.E., Russell, L.B., and Weinstein, M.C. (eds.) (1996). Cost-effectiveness in health and medicine. Oxford University Press, New York, NY.
Gold, M.R., Stevenson, D., and Fryback, D.G. (2002). HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population health. Annu. Rev. Public Health 23:115–134.
Graham, J.D. (1995). Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15:369–90.
Harris, J. (1987). QALYfying the value of life. J. Med. Ethics 13:117–23.
Hershey, J.C., Kunreuther, H.C., and Schoemaker, P.J.H. (1988). Sources of bias in assessment procedures for utility functions. In: Bell, D.E., Raiffa, H. and Tversky, A. (eds.), Decision making: Descriptive, normative, and prescriptive interactions. Cambridge University Press, Cambridge; New York and Melbourne, pp. 422–42.
Hoch, J., and Bayoumi, A. (2003). Mary had a little lambda: incorporating group-specific values into cost-effectiveness analysis using the net benefit regression framework. 25th Annual Meeting of the Society for Medical Decision Making, Chicago, IL (Abstract).
Hoch, J.S., Briggs, A.H., and Willan, A.R. (2002). Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health. Econ. 11:415–430.
Holm, S. (1998). The second phase of priority setting. Goodbye to the simple solutions: The second phase of priority setting in health care. BMJ. 317:1000–2.
Hornberger, J.C., Redelmeier, D.A., and Petersen, J. (1992). Variability among methods to assess patients’ well-being and consequent effect on a cost-effectiveness analysis. J. Clin. Epidemiol. 45:505–12.
International Society for Pharmacoeconomics and Outcomes Research, 2004, Pharmacoeconomic Guidelines Around The World. (September 15, 2004); http://www.ispor.org/PEguidelines/index.asp.
Klose, T., (1999). The contingent valuation method in health care. Health Policy 47:97–123.
Laupacis, A., Feeny, D., Detsky, A.S., and Tugwell, P.X. (1993). Tentative guidelines for using clinical and economic evaluations revisited. CMAJ. 148:927–9.
Lallemant, M., Jourdain, G., Le Coeur, S., Mary, J.Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K., and Thaineua, V. (2004). Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351:217–228.
Lansky, A., Jones, J.L., Frey, R.L., and Lindegren, M.L. (2001). Trends in HIV testing among pregnant women: United States, 1994–1999. Am. J. Public Health 91:1291–1293.
Laufer, F.N. (2001). Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir. Immune. Defic. Syndr. 28:273–278.
Llewellyn-Thomas, H., Sutherland, H.J., Tibshirani, R., Ciampi, A., Till, J.E., and Boyd, N.F. (1984). Describing health states. Methodologic issues in obtaining values for health states. Med. Care 22:543–52.
Llewellyn-Thomas, H., Sutherland, H.J., Tibshirani, R., Ciampi, A., Till, J.E., and Boyd, N.F. (1982). The measurement of patients’ values in medicine. Med. Decis. Making 2:449–62.
Loomes, G., and McKenzie, L. (1989). The use of QALYs in health care decision making. Soc. Sci. Med. 28:299–308.
Luce, B.R., Manning, W., Siegel, J.E., and Lipscomb, J. (1996). Estimating costs in cost-effectiveness analysis. In: Gold, M.R., Seigel, J.E., Russell, L.B. and Weinstein, M.C. (eds.), Cost-effectiveness in health and medicine. Oxford University Press, New York, pp. 176–213.
Martin, A.J., Glasziou, P.P., Simes, R.J., and Lumley, T. (2000). A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int. J. Technol. Assess. Health Care 16:137–47.
McGregor, M. (2003). Cost-utility analysis: use QALYs only with great caution. CMAJ 168:433–4.
Mehrez, A., and Gafni, A. (1989). Quality-adjusted life years, utility theory, and healthy-years equivalents. Med. Decis. Making 9:142–9.
Mehrez, A., and Gafni, A. (1993). Healthy-years equivalents versus quality-adjusted life years: In pursuit of progress. Med. Decis. Making 13:287–92.
McIntosh, E., Donaldson, C., and Ryan, M. (1999). Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science. Pharmacoeconomics 15:357–67.
Nord, E. (1992). An alternative to QALYs: the saved young life equivalent (SAVE). BMJ. 305(6865):1365–6.
Nord, E. (1995). The person-trade-off approach to valuing health care programs. Med. Decis. Making 15:201–8.
Oliver, A., Healey, A., and Donaldson, C. (2002). Choosing the method to match the perspective: economic assessment and its implications for health-services efficiency. Lancet 359:1771–4.
Owens, D.K. (1998). Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 13:716–7.
Owens, D.K., and Nease, R.F. (1997). A normative analytic framework for development of practice guidelines for specific clinical populations. Med. Decis. Making 17:409–426.
O’Brien, B., and Gafni, A. (1996). When do the “dollars” make sense? Toward a conceptual framework for contingent valuation studies in health care. Med. Decis. Making 16:288–99.
Olsen, J.A., and Smith, R.D. (2001). Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ. 10:39–52.
Phillips, K.A., Bayer, R., and Chen, J.L. (2003). New Centers for Disease Control and Prevention’s guidelines on HIV counseling and testing for the general population and pregnant women. J. Acquir. Immune. Defic. Syndr. 32:182–191.
Powderly, K. (2001). Ethical and legal issues in perinatal HIV. Clin. Obstet. Gynecol. 44:300–311.
Read, J.L., Quinn, R.J., Berwick, D.M., Fineberg, H.V., and Weinstein, M.C. (1984). Preferences for health outcomes. Comparison of assessment methods. Med. Decis. Making 4:315–29.
Redelmeier, D.A., and Heller, D.N. (1993). Time preference in medical decision making and cost-effectiveness analysis. Med. Decis. Making 13:212–7.
Ried, W. (1998). QALYs versus HYEs-What’s right and what’s wrong. A review of the controversy. J. Health Econ. 17:607–25.
Sculpher, M., Fenwick, E., and Claxton, K. (2000). Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 17:461–477.
Singer, P., McKie, J., Kuhse, H., and Richardson, J. (1995). Double jeopardy and the use of QALYs in health care allocation. J. Med. Ethics 21:144–50.
Stiggelbout, A.M., Kiebert, G.M., Kievit, J., Leer, J.W., Stoter, G., and De Haes, J.C. (1994). Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med. Decis. Making 14:82–90.
Stinnett, A.A., and Paltiel, A.D. (1997). Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med. Decis. Making 17:483–489.
Tengs, T.O., Adams, M.E., Pliskin, J.S., Safran, D.G., Siegel, J.E., Weinstein, M.C., and Graham, J.D. (1995). Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15(3):369–90.
Torrance, G.W. (1976). Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Planning Sci. 10:129–136.
Torrance, G.W. (1987). Utility approach to measuring health-related quality of life. J. Chronic Dis. 40:593–603.
Torrance, G.W. (1986). Measurement of health state utilities for economic appraisal. J. Health Econ. 5:1–30.
Tsevat, J., Solzan, J., Kuntz, K., Ragland, J., Currier, J., Sell, R., and Weinstein, M. (1996). Health values of patients infected with Human Immunodeficiency Virus: relationship to mental health and physical functioning. Med. Care 34:44–57.
Ubel, P.A., DeKay, M.L., Baron, J., and Asch, D.A. (1996). Cost-effectiveness analysis in a setting of budget constraints-Is it equitable? N. Engl. J. Med. 334:1174–7.
Ubel, P.A., Nord, E., Gold, M., Menzel, P., Prades, J.L., and Richardson, J. (2000). Improving value measurement in cost-effectiveness analysis. Med. Care 38:892–901.
Wagstaff, A. (1991). QALYs and the equity-efficiency trade-off. J. Health Econ. 10:21–41.
Wade, N.A., Zielinski, M.A., Butsashvili, M., McNutt, L.A., Warren, B.L., Glaros, R., Cheku, B., Pulver, W., Pass, K., Fox, K., Novello, A.C., and Birkhead, G.S. (2004). Decline in Perinatal HIV Transmission in New York State (1997–2000). J Acquir. Immune. Defic. Syndr. 36:1075–1082.
Wailoo, A., Roberts, J., Brazier, J., and McCabe, C. (2004). Efficiency, equity, and NICE clinical guidelines. BMJ. 328:536–537.
Webber, M.P., Van Dyke, R., Wiener, J., and Branson, B.M. (2004). Rapid HIV-1 testing during labor: a multicenter study. JAMA. 292:219–223.
Weinstein, M.C. (ed.), Cost-effectiveness in health and medicine. Oxford University Press, New York, pp. 25–53.
Weinstein, M.C., and Stason, W.B. (1977). Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. 296:716–21.
Williams, A. (1991). Is the QALY a technical solution to a political problem? Of course not! Int. J. Health Serv. 21:365–9.
Zaric, G.S., Bayoumi, A.M., Brandeau, M.L., and Owens, D.K. (2000). The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir. Immune. Defic. Syndr. 25:403–16.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+ Business Media, Inc.
About this chapter
Cite this chapter
Bayoumi, A.M. (2005). Cost-Effectiveness Analysis for Urban Health Research. In: Galea, S., Vlahov, D. (eds) Handbook of Urban Health. Springer, Boston, MA . https://doi.org/10.1007/0-387-25822-1_21
Download citation
DOI: https://doi.org/10.1007/0-387-25822-1_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-23994-1
Online ISBN: 978-0-387-25822-5
eBook Packages: MedicineMedicine (R0)